PIK3CA and hepatocellular carcinoma: In a xenograft model in female BALB/c- mice bearing Hep3B cells, when subjected to IP ISL (50 mg/kg/day for three weeks) administration, they showed decreased tumorigenesis and metastasis of HCC due to a reduction in the expression of cyclin D1 and the suppression of the PI3K/AKT pathway [108].